Tag - OSMT

Developments

FDA approves Osmotica Pharma’s Upneeq for blepharoptosis

The FDA approved Osmotica Pharmaceuticals’ (NASDAQ:OSMT) Upneeq for the treatment of acquired blepharoptosis, an abnormal drooping of the upper eyelid that can limit field of vision. Acquired blepharoptosis is often...

July 9, 2020

Markets

SVB Leerink starts Osmotica Pharma at OP; PT $10

SVB Leerink launched coverage of Osmotica Pharmaceuticals (NASDAQ:OSMT) with an “outperform rating” and $10 price target. The stock closed at $5.47 on March 5. Analyst Ami Fadia writes that her rating is based on the...

March 6, 2020

Tag - OSMT

FDA approves Osmotica Pharma’s Upneeq for blepharoptosis

SVB Leerink starts Osmotica Pharma at OP; PT $10

General

More